Arastehfar Amir, Daneshnia Farnaz, Hilmioglu-Polat Süleyha, Ilkit Macit, Yasar Melike, Polat Furkan, Metin Dilek Yeşim, Dokumcu Ülküm Zafer, Pan Weihua, Hagen Ferry, Boekhout Teun, Perlin David S, Lass-Flörl Cornelia
Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, NJ 07110, USA.
Westerdijk Fungal Biodiversity Institute, Utrecht, The Netherlands.
J Antimicrob Chemother. 2021 Jan 19;76(2):418-422. doi: 10.1093/jac/dkaa419.
Echinocandin resistance rarely occurs in clinical Candida parapsilosis isolates and the underlying mechanism is unknown.
To determine the prevalence of echinocandin resistance and the underlying mechanism for a large collection of C. parapsilosis blood isolates and to determine whether the echinocandin-resistant isolates were clonally related.
C. parapsilosis blood isolates (n = 213) were subjected to antifungal susceptibility testing (CLSI M27), for micafungin, anidulafungin, amphotericin B and, if appropriate, caspofungin. Hotspot (HS) 1 and HS2 of FKS1 were sequenced for all isolates (n = 213) and microsatellite typing was performed for echinocandin-resistant isolates.
All isolates were susceptible to amphotericin B and two isolates were intermediate to anidulafungin (MIC = 4 mg/L), while micafungin resistance was noted in four isolates (MIC >8 mg/L); three of which were also fluconazole resistant and therefore were MDR. Interestingly, micafungin-resistant isolates, but not those intermediate to anidulafungin, carried novel mutation R658G in HS1 of Fks1p; three of which also harboured Y132F+K143R in Erg11. The first isolate (MICR1) was recovered in November 2017 from a patient admitted to paediatric gastroenterology who showed therapeutic failure under caspofungin treatment. MICR2-MICR4 were collected during 2018-19 and were recovered from three echinocandin-naive paediatric-surgery patients; the isolates shared the same genotype.
Herein, for the first time (to the best of our knowledge), we identified micafungin-resistant C. parapsilosis blood isolates harbouring a novel mutation in HS1 of FKS1, which was likely attributable to in vitro micafungin resistance and in vivo caspofungin therapeutic failure. The acquisition of micafungin-resistant C. parapsilosis isolates in echinocandin-naive patients likely implicates clonal expansion, as supported by the close genetic relatedness of MICR2-MICR4.
棘白菌素耐药在临床近平滑念珠菌分离株中很少见,其潜在机制尚不清楚。
确定大量近平滑念珠菌血液分离株中棘白菌素耐药的发生率及其潜在机制,并确定棘白菌素耐药分离株是否存在克隆相关性。
对近平滑念珠菌血液分离株(n = 213)进行抗真菌药敏试验(CLSI M27),检测米卡芬净、阿尼芬净、两性霉素B,以及在适当情况下检测卡泊芬净。对所有分离株(n = 213)的FKS1热点(HS)1和HS2进行测序,并对棘白菌素耐药分离株进行微卫星分型。
所有分离株对两性霉素B敏感,2株对阿尼芬净中介(MIC = 4mg/L),4株对米卡芬净耐药(MIC > 8mg/L);其中3株对氟康唑也耐药,因此为多重耐药。有趣的是,对米卡芬净耐药的分离株,而非对阿尼芬净中介的分离株,在Fks1p的HS1中携带新突变R658G;其中3株在Erg11中也携带Y132F + K143R。第一株分离株(MICR1)于2017年11月从一名儿科胃肠病科住院患者中分离得到,该患者在卡泊芬净治疗下出现治疗失败。MICR2 - MICR4于2018 - 2019年期间收集,从3名未使用过棘白菌素的儿科手术患者中分离得到;这些分离株具有相同的基因型。
据我们所知,我们首次鉴定出在FKS1的HS1中携带新突变的对米卡芬净耐药的近平滑念珠菌血液分离株,这可能是体外米卡芬净耐药和体内卡泊芬净治疗失败的原因。在未使用过棘白菌素的患者中获得对米卡芬净耐药的近平滑念珠菌分离株可能意味着克隆扩增,MICR2 - MICR4的密切遗传相关性支持了这一点。